GLPG - ガラパゴス (Galapagos NV) ガラパゴス

 GLPGのチャート


 GLPGの企業情報

symbol GLPG
会社名 Galapagos NV (ガラパゴス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種    医療関連(Health Care)
概要 事業概要 --   ガラパゴスは、ベルギ―のバイオ医薬品企業。炎症性疾患、変形性関節症、腫瘍、クロ―ン病などの臨床段階で、抗体療法などの新薬開発に従事する。主な医薬品候補には、関節リウマチ治療薬「GLPG0634」、炎症性腸疾患治療薬「GLPG1205」などがある。設立は1999年、本社をメヘレンに置く。   
本社所在地 Generaal De Wittelaan L11 A3 Mechelen B-2800 BEL
代表者氏名
代表者役職名
電話番号
設立年月日 1999年
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 600人
url www.glpg.com
nasdaq_url https://www.nasdaq.com/symbol/glpg
adr_tso 8838607
EBITDA EBITDA ー
終値(lastsale) 100.745
時価総額(marketcap) 890445462.215
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 GLPGのテクニカル分析


 GLPGのニュース

   The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq  2021/03/18 12:16:32 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 17) AngioDynamics, Inc. (NASDAQ: ANGO ) Anixa Biosciences, Inc. (NASDAQ: ANIX ) BioAtla, Inc. (NASDAQ: BCAB ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) IDEAYA Biosciences, Inc. (NASDAQ: IDYA ) Immatics N.V. (NASDAQ: IMTX ) ( announced positive Phase 1 readout for a trio of candidates in solid tumors) NGM Biopharmaceuticals, Inc. (NASDAQ: NGM ) NuVasive, Inc. (NASDAQ: NUVA ) Omnicell, Inc. (NASDAQ: OMCL ) Oncternal Therapeutics, Inc. (NASDAQ: ONCT ) Organogenesis Holdings Inc. (NASDAQ: ORGO ) PLx Pharma Inc. (NASDAQ: PLXP ) Sierra Oncology, Inc. (NASDAQ: SRRA ) Silverback Therapeutics, Inc. (NASDAQ: SBTX ) STRATA Skin Sciences, Inc. (NASDAQ: SSKN ) Urovant Sciences Ltd. (NASDAQ: UROV ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 17) Foghorn Therapeutics Inc. (NASDAQ: FHTX ) Galapagos NV (NASDAQ: GLPG ) Galecto, Inc. (NASDAQ: GLTO ) Stocks In Focus Translate Bio mRNA Product Candidate For Cystic Fibrosis Fails To Improve Lung Function In Phase 1/2 Study Translate Bio (NASDAQ: TBIO ) announced a second interim analysis from the Phase 1/2 study of MRT5005 in patients with cystic fibrosis, showing that repeat dosing was generally safe and well tolerated, with no serious adverse events.
   Slotcall: Weer die financials  2021/03/08 16:50:00 IEX.nl
AEX +1,8% en een rondje langs ABN Amro, PostNL, Deutsche Post, Accel, Royal Dutch Shell, Galapagos, Unibail Rodamco, GrandVision, Sligro en meer!
   Stocks That Hit 52-Week Lows On Friday  2021/02/12 10:04:00 Benzinga
Friday's morning session saw 4 companies set new 52-week lows. Things to Consider: Galapagos (NASDAQ:GLPG) was the largest firm on a …
   Gilead, Galapagos halt IPF study in latest stumble for blockbuster alliance - MedCity News  2021/02/10 22:17:20 MedCity News
The decision to discontinue all clinical trials for ziritaxestat is the latest setback in a broad alliance between Gilead Sciences and Galapagos. Last year, the FDA rejected a rheumatoid arthritis drug covered under the partnership.
   Gilead’s Galapagos deal disintegrates, a black mark for CEO O’Day - STAT  2021/02/10 16:04:00 STAT News
A $5 billion deal to develop a drug called zirataxestat, for idiopathic pulmonary fibrosis, goes up in flames.
   Gilead, Galapagos amend commercialisation and development pact for Jyseleca (filgotinib) - Express Pharma  2020/12/16 06:20:14 Express Pharma
Under the new arrangement, Galapagos will assume sole responsibility in Europe for filgotinib in RA, Gilead to receive royalties on European sales starting in 2024
   Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib)  2020/12/15 21:15:00 Business Wire
FOSTER CITY, Calif. & MECHELEN, Belgium--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the companies have agreed to amend their existing arrangement for the commercialization and development of Jyseleca (filgotinib). This announcement follows a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the points raised in the Complete Response Letter (CRL) related to the New Drug Application (NDA) for f
   Galapagos increases share capital through subscription right exercises  2020/12/04 21:01:00 GlobeNewswire
Mechelen, Belgium; 4 December 2020, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase…
   News briefing: Gilead partner Galapagos sells off CRO for $37M; Polyphor bags $3.3M from CF Foundation  2020/11/24 16:22:08 Endpoints News
Close Gilead ally Galapagos is selling off one of its contract research organizations to a Polish pharma company. Galapagos has agreed to sell 100% of the outstanding shares in the CRO Fidelta to Selvita, in a deal worth roughly $37 million expected to close in the first week of January.
   Galapagos reports Q3 2020 results  2020/11/05 21:01:00 GlobeNewswire
First nine months 2020 financial results: Group revenues and other income of €368.6 millionOperating loss of €163.2 millionNet loss of €247.6 millionCash…
   Galapagos increases share capital through subscription right exercises  2020/12/04 21:01:00 GlobeNewswire
Mechelen, Belgium; 4 December 2020, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase…
   News briefing: Gilead partner Galapagos sells off CRO for $37M; Polyphor bags $3.3M from CF Foundation  2020/11/24 16:22:08 Endpoints News
Close Gilead ally Galapagos is selling off one of its contract research organizations to a Polish pharma company. Galapagos has agreed to sell 100% of the outstanding shares in the CRO Fidelta to Selvita, in a deal worth roughly $37 million expected to close in the first week of January.
   Galapagos reports Q3 2020 results  2020/11/05 21:01:00 GlobeNewswire
First nine months 2020 financial results: Group revenues and other income of €368.6 millionOperating loss of €163.2 millionNet loss of €247.6 millionCash…
   Galapagos (NASDAQ:GLPG) Upgraded by Zacks Investment Research to Hold  2020/10/25 01:14:41 Stock Observer
Zacks Investment Research upgraded shares of Galapagos (NASDAQ:GLPG) from a strong sell rating to a hold rating in a research report report published on Wednesday morning, Zacks.com reports. According to Zacks, “Galapagos NV is a biotechnology company. The Company’s operating segment consists of Research and Development and Services. Research and Development segment is engaged in […]
   Goldman Sachs Group Lowers Galapagos (NASDAQ:GLPG) to Sell  2020/10/24 04:54:41 Stock Observer
Goldman Sachs Group downgraded shares of Galapagos (NASDAQ:GLPG) from a neutral rating to a sell rating in a research note released on Wednesday morning, AnalystRatings.net reports. Several other equities research analysts have also weighed in on GLPG. Bank of America dropped their target price on Galapagos from $148.00 to $134.00 and set an underperform rating […]

 関連キーワード  (― 米国株 ガラパゴス GLPG Galapagos NV)

 twitter  (公式ツイッターやCEOツイッターなど)